BACKGROUND:Oral naltrexone is an efficacious medication for treatment of alcohol dependence, but small effect sizes and variability in outcomes suggest the presence of person-level moderators of naltrexone response. Identification of contextual or psychosocial moderators may assist in guiding clinical recommendations. Given the established importance of social networks in drinking outcomes, as well as the potential effects of naltrexone in reducing cue reactivity which may be especially important among those with more heavy drinkers and more alcohol cues in their networks, we examined pretreatment social network variables as potential moderators of naltrexone treatment effects in the COMBINE study. METHODS: The sample included all COMBINE study participants in medication conditions with full data on the Important People Inventory (IPI) and covariates at intake (N = 1,197). The intake IPI assessed whether participants had any frequent drinkers in their network and the average frequency of contact with these drinkers. The effects of treatment condition, pretreatment network variables, and their interactions on percent heavy drinking days were tested in hierarchical linear models, controlling for demographics and baseline clinical covariates. RESULTS: In treatment conditions involving medical management and combined behavioral intervention (CBI), the effects of active naltrexone on heavy drinking were significantly greater for individuals with frequent drinkers in their network (z = -2.66, p < 0.01) and greater frequency of contact with those drinkers (z = -3.19, p < 0.01). These network variables did not moderate the effects of active naltrexone without CBI. CONCLUSIONS: When delivered in conjunction with behavioral interventions, naltrexone can be more potent for alcohol-dependent adults who have greater contact with frequent drinkers prior to treatment, which may indicate patterns of environmental exposure to alcohol. Contextual, social risk factors are a potential avenue to guide personalized treatment of alcohol dependence.
RCT Entities:
BACKGROUND: Oral naltrexone is an efficacious medication for treatment of alcohol dependence, but small effect sizes and variability in outcomes suggest the presence of person-level moderators of naltrexone response. Identification of contextual or psychosocial moderators may assist in guiding clinical recommendations. Given the established importance of social networks in drinking outcomes, as well as the potential effects of naltrexone in reducing cue reactivity which may be especially important among those with more heavy drinkers and more alcohol cues in their networks, we examined pretreatment social network variables as potential moderators of naltrexone treatment effects in the COMBINE study. METHODS: The sample included all COMBINE study participants in medication conditions with full data on the Important People Inventory (IPI) and covariates at intake (N = 1,197). The intake IPI assessed whether participants had any frequent drinkers in their network and the average frequency of contact with these drinkers. The effects of treatment condition, pretreatment network variables, and their interactions on percent heavy drinking days were tested in hierarchical linear models, controlling for demographics and baseline clinical covariates. RESULTS: In treatment conditions involving medical management and combined behavioral intervention (CBI), the effects of active naltrexone on heavy drinking were significantly greater for individuals with frequent drinkers in their network (z = -2.66, p < 0.01) and greater frequency of contact with those drinkers (z = -3.19, p < 0.01). These network variables did not moderate the effects of active naltrexone without CBI. CONCLUSIONS: When delivered in conjunction with behavioral interventions, naltrexone can be more potent for alcohol-dependent adults who have greater contact with frequent drinkers prior to treatment, which may indicate patterns of environmental exposure to alcohol. Contextual, social risk factors are a potential avenue to guide personalized treatment of alcohol dependence.
Authors: Gabor Oroszi; Raymond F Anton; Stephanie O'Malley; Robert Swift; Helen Pettinati; David Couper; Qiaoping Yuan; David Goldman Journal: Alcohol Clin Exp Res Date: 2008-11-25 Impact factor: 3.455
Authors: Lara A Ray; Kent E Hutchison; James MacKillop; Robert Miranda; Amy Audette; Robert Swift; Peter M Monti Journal: Am J Addict Date: 2008 Jul-Aug
Authors: Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman Journal: Arch Gen Psychiatry Date: 2008-02
Authors: Lara A Ray; Spencer Bujarski; Megan M Yardley; Daniel J O Roche; Emily E Hartwell Journal: Am J Drug Alcohol Abuse Date: 2017-04-20 Impact factor: 3.829
Authors: Ralitza Gueorguieva; Ran Wu; Wan-Min Tsai; Patrick G O'Connor; Lisa Fucito; Heping Zhang; Stephanie S O'Malley Journal: Eur Neuropsychopharmacol Date: 2015-06-20 Impact factor: 4.600
Authors: Julianne C Flanagan; Jane E Joseph; Paul J Nietert; Sudie E Back; Barbara S McCrady Journal: Contemp Clin Trials Date: 2019-05-04 Impact factor: 2.226
Authors: Katie Witkiewitz; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Corey R Roos; Megan Kirouac; Adam D Wilson; Kevin S Montes; Nick Heather Journal: Addiction Date: 2017-06-26 Impact factor: 6.526
Authors: Carolina L Haass-Koffler; Daria Piacentino; Xiaobai Li; Victoria M Long; Mary R Lee; Robert M Swift; George A Kenna; Lorenzo Leggio Journal: Alcohol Clin Exp Res Date: 2020-09-30 Impact factor: 3.928